Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Cash & Equivalents (2016 - 2025)

Lexaria Bioscience's Cash & Equivalents history spans 11 years, with the latest figure at $4.3 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 47.0% year-over-year to $4.3 million; the TTM value through Nov 2025 reached $4.3 million, down 47.0%, while the annual FY2025 figure was $1.8 million, 72.27% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $4.3 million at Lexaria Bioscience, up from $1.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $10.9 million in Q3 2021 and bottomed at $1.4 million in Q3 2023.
  • The 5-year median for Cash & Equivalents is $6.1 million (2022), against an average of $5.9 million.
  • The largest annual shift saw Cash & Equivalents skyrocketed 1743.04% in 2021 before it tumbled 76.74% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $9.7 million in 2021, then crashed by 53.18% to $4.5 million in 2022, then plummeted by 56.89% to $2.0 million in 2023, then soared by 313.39% to $8.1 million in 2024, then crashed by 47.0% to $4.3 million in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Cash & Equivalents are $4.3 million (Q4 2025), $1.8 million (Q3 2025), and $4.6 million (Q2 2025).